• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Profound Medical Corp. (Amendment)

    2/12/24 2:37:47 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care
    Get the next $PROF alert in real time by email
    SC 13G/A 1 profdmed1223.txt SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No One) PROFOUND MEDICAL CORP. .............. (Name of Issuer) COMMON SHARES ....................................................................... (Title of Class of Securities) 74319B502 ......................................................................... (CUSIP Number) December 31, 2023 ................................................ (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 74319B502 (1)Names of reporting persons. I.R.S. Identification Nos. of above persons (entities only) LETKO, BROSSEAU & ASSOCIATES INC. (2) Check the appropriate box if a member of a group (see instructions) (a) (b) (3) SEC use only (4) Citizenship or place of organization CANADA Number of shares beneficially owned by each reporting person with: (5)Sole voting power 1,177,850 (6)Shared voting power (7)Sole dispositive power 1,177,850 (8)Shared dispositive power (9)Aggregate amount beneficially owned by each reporting person 1,177,850 (10)Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11)Percent of class represented by amount in Row 9 5.5% (12)Type of reporting person (see instructions) FI Item 1. Item 1(a) Name of issuer: PROFOUND MEDICAL CORP. Item 1(b) Address of issuer's principal executive offices: 2400 Skymark Avenue Unit 6 Mississauga, ON L4W 5K5 Canada Item 2. 2(a) Name of person filing: Letko, Brosseau & Associates Inc. 2(b) Address or principal business office or, if none, residence: 1800 Mc Gill College Av. Suite 2510 Montreal, QC H3A 3J6 Canada 2(c) Citizenship: Canada 2(d) Title of class of securities: Common Shares 2(e) CUSIP No.: 74319B502 Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b)or(c), check whether the person filing is a: a. [ ] Broker or dealer registered under Section 15 of the Act. b. [ ] Bank as defined in Section 3(a)(6) of the Act. c. [ ] Insurance company as defined in Section 3(a)(19) of the Act. d. [ ] Investment company registered under Section 8 of the Investment Company Act of 1940. e. [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); f. [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); g. [ ] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); h. [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); i. [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; j. [x] A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); k. [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K). Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. a. Amount beneficially owned: 1,177,850 b. Percent of class: 5.5% c. Number of shares as to which such person has: i. Sole power to vote or to direct the vote: 1,177,850 ii. Shared power to vote or to direct the vote iii. Sole power to dispose or to direct the disposition of: 1,177,850 iv. Shared power to dispose or to direct the disposition of Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following []. Item 6. Ownership of More than 5 Percent on Behalf of Another Person Clients of Letko, Brosseau & Associates Inc. have the right to receive or the power to direct the receipt of dividends from, or the proceeds from sale of, the common shares reported as beneficially owned by Letko, Brosseau & Associates Inc. No clients of Letko, Brosseau & Associates Inc. beneficially owns more than five percent of Issuer's Common Shares. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not Applicable Item 8. Identification and Classification of Members of the Group Not Applicable Item 9. Notice of Dissolution of Group Not Applicable Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business, were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated : February 12, 2024 Signature Isabelle Godin Name/Title: Isabelle Godin Chief Financial Officer and Chief Compliance Officer
    Get the next $PROF alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PROF

    DatePrice TargetRatingAnalyst
    7/23/2024$16.50Buy
    Lake Street
    7/16/2024$9.00 → $12.00Hold → Buy
    Stifel
    11/28/2023$11.00Hold
    Stifel
    8/4/2023$20.00 → $200.00Strong Buy → Outperform
    Raymond James
    3/21/2023$5.50 → $10.00Buy → Hold
    Jefferies
    3/7/2022$28.00 → $14.00Outperform
    Cowen & Co.
    2/22/2022$28.00 → $23.00Strong Buy → Outperform
    Raymond James
    More analyst ratings

    $PROF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Profound Medical Announces Second Quarter 2025 Financial Results

    TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the second quarter ended June 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Utilization of current TULSA-PRO® systems continues to grow, with "same store" procedure volumes up 10% sequentially from Q1-2

    8/14/25 4:05:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

    TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2025 financial results after market close on Thursday, August 14, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Second Quarter 2025 Results Conference Call Details: Date: Thursday, August 14, 2025 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BId8

    7/24/25 5:00:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Announces First Commercial BPH Patient Treatment Using TULSA-PRO® with TULSA-AI® Volume Reduction

    TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce that the first commercial benign prostatic hyperplasia ("BPH") treatment utilizing the TULSA-PRO® system's new TULSA-AI® Volume Reduction Module was successfully conducted yesterday by Naveen Kella, M.D., Founder of The Urology Place and an Adjunct Assistant Professor for the UT Health Science Center San Antonio. BPH is a non-cancerous enlargement of the prostate gland due to an overgrowth of pro

    6/10/25 8:00:00 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Menawat Arun Swarup bought $100,151 worth of shares (22,030 units at $4.55), increasing direct ownership by 4% to 587,089 units (SEC Form 4)

    4 - Profound Medical Corp. (0001628808) (Issuer)

    5/20/25 1:56:42 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Profound Medical with a new price target

    Lake Street initiated coverage of Profound Medical with a rating of Buy and set a new price target of $16.50

    7/23/24 8:51:59 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical upgraded by Stifel with a new price target

    Stifel upgraded Profound Medical from Hold to Buy and set a new price target of $12.00 from $9.00 previously

    7/16/24 7:45:31 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on Profound Medical with a new price target

    Stifel initiated coverage of Profound Medical with a rating of Hold and set a new price target of $11.00

    11/28/23 7:53:24 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    SEC Filings

    View All

    Profound Medical Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Profound Medical Corp. (0001628808) (Filer)

    8/14/25 4:11:01 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Profound Medical Corp. (0001628808) (Filer)

    6/4/25 1:30:59 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Profound Medical Corp.

    8-K - Profound Medical Corp. (0001628808) (Filer)

    5/14/25 5:20:48 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Menawat Arun Swarup bought $100,151 worth of shares (22,030 units at $4.55), increasing direct ownership by 4% to 587,089 units (SEC Form 4)

    4 - Profound Medical Corp. (0001628808) (Issuer)

    5/20/25 1:56:42 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Financials

    Live finance-specific insights

    View All

    Profound Medical Announces Second Quarter 2025 Financial Results

    TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the second quarter ended June 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Utilization of current TULSA-PRO® systems continues to grow, with "same store" procedure volumes up 10% sequentially from Q1-2

    8/14/25 4:05:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

    TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2025 financial results after market close on Thursday, August 14, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Second Quarter 2025 Results Conference Call Details: Date: Thursday, August 14, 2025 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BId8

    7/24/25 5:00:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Announces First Quarter 2025 Financial Results

    TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the first quarter ended March 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).  Business Highlights Q1-2025 revenue growth of 82% over Q1-2024. Profound continued to see a wide variety of prostate disease patients treated by

    5/8/25 4:05:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Leadership Updates

    Live Leadership Updates

    View All

    Profound Medical Annual General and Special Meeting of Shareholders Voting Results

    TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 4, 2025 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders

    5/14/25 4:45:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

    – Mr. Tamberrino and Profound's CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final preparations for the permanent CPT® Category 1 codes for TULSA going into effect at the beginning of 2025 – TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the appointment of Tom Tamberrino as its new Chief Commercial Officer. Abbey Goodman, the Company's current CCO, will t

    10/16/24 4:15:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Annual General Meeting of Shareholders Voting Results

    TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Comp

    5/15/24 5:00:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Profound Medical Corp.

    SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

    11/14/24 4:27:34 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Profound Medical Corp.

    SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

    8/5/24 7:50:30 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Profound Medical Corp. (Amendment)

    SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

    3/13/24 4:00:16 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care